BLOG
Manufacturers Don’t Forget: Virginia Drug Pricing Reports are Due April 1st
Manufacturers Don’t Forget: Virginia Drug Pricing Reports are Due April 1st March 2021, Virginia passed the Prescription Drug Price Transparency Regulation requiring pharmaceutical manufacturers to annually report prescription drug pricing information. The State Board...
Recent Articles
New York Opioid Treatment Funding: Cut Off One Head, Two Grow Back
New York Opioid Treatment Funding: Cut Off One Head, Two Grow Back The pharmaceutical supply chain industry is now funding New York’s efforts to...
Changes Rumored to Be on Horizon for DEA Suspicious Orders
Changes Rumored to Be on Horizon for DEA Suspicious Orders Public interest in the Opioid Epidemic has taken a back seat to this year’s events...
Vermont Updates Rules to Align Regulation with the DSCSA – And Then Some
Vermont Updates Rules to Align Regulation with the DSCSA – And Then Some The DSCSA has had wide-ranging implications on state regulation of the...
Licensing Issues Causes Public Skirmish with State Boards for Drug Companies
The patchwork that is state licensure is a constant challenge for all companies in the pharmaceutical supply chain – from international drug manufacturers to independent distributors. Companies not in compliance are at significant risk of being caught by state agencies and facing significant fines, having disciplinary action follow them for years, and, in one example, being forced to close their business. Most important to remember is that non-compliance typically sets off a chain reaction.
DSCSA to Cause Future State Regulation Changes
DSCSA to Cause Future State Regulation Changes State regulation of the pharmaceutical supply chain is a patchwork of different definitions,...
Morphine Equivalency for Suspicious Order Monitoring
Morphine Equivalency for Suspicious Order Monitoring Background In July 2016, at the height of the opioid epidemic, the West Virginia Attorney...
